Stay updated on Clinical Trial: Salvage Therapies in NK/T Cell Lymphoma
Sign up to get notified when there's something new on the Clinical Trial: Salvage Therapies in NK/T Cell Lymphoma page.

Latest updates to the Clinical Trial: Salvage Therapies in NK/T Cell Lymphoma page
- ChecktodayChange DetectedThe new screenshot shows the same study details (PD-1 pembrolizumab in relapsed/refractory NK/T cell lymphoma) with only minor layout and labeling differences; there are no changes to core content such as enrollment, primary outcomes, or eligibility criteria. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

 - Check7 days agoNo Change Detected
 - Check29 days agoChange DetectedMajor addition of a government funding notice and upgrade to v3.2.0, replacing v3.1.0; references to operating status and status inquiries are now present.SummaryDifference5%

 - Check36 days agoChange DetectedUpdated terminology and versioning: standardizes the condition name to NK/T cell lymphoma and updates the page from v3.0.2 to v3.1.0, plus addition of contact-like identifiers.SummaryDifference0.4%

 - Check50 days agoChange DetectedRevision updated to v3.0.2; Back to Top removed. No changes to core content or critical information.SummaryDifference0.3%

 - Check57 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. Additionally, a 'Back to Top' feature has been added for improved navigation.SummaryDifference0.3%

 - Check65 days agoChange DetectedThe page has undergone significant updates, including the addition of a facility name and location, as well as the introduction of specific lymphoma-related terms and the drug pembrolizumab. Notably, the previous version's detailed medical topics and terms have been largely removed.SummaryDifference6%

 
Stay in the know with updates to Clinical Trial: Salvage Therapies in NK/T Cell Lymphoma
Enter your email address, and we'll notify you when there's something new on the Clinical Trial: Salvage Therapies in NK/T Cell Lymphoma page.